Adibzadeh Setare, Amiri Shahin, Nia Giti Esmail, Taleghani Maryam Rezakhani, Bijarpas Zahra Kohanrooz, Maserat Neda, Maali Amirhosein, Azad Mehdi, Behzad-Behbahani Abbas
Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Student Research Committee, Pasteur Institute of Iran, Tehran, Iran.
Gene Rep. 2022 Jun;27:101619. doi: 10.1016/j.genrep.2022.101619. Epub 2022 May 4.
Coronavirus disease 2019 (COVID-19) is a remarkably contagious and pathogenic viral infection arising from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan, China. For the time being, COVID-19 is not treated with a specific therapy. The Food and Drug Administration (FDA) has approved Remdesivir as the first drug to treat COVID-19. However, many other therapeutic approaches are being investigated as possible treatments for COVID-19. As part of this review, we discussed the development of various drugs, their mechanism of action, and how they might be applied to different cases of COVID-19 patients. Furthermore, this review highlights an update in the emergence of new prophylactic or therapeutic vaccines against COVID-19. In addition to FDA or The World Health Organization (WHO) approved vaccines, we intended to incorporate the latest published data from phase III trials about different COVID-19 vaccines and provide clinical data released on the networks or peer-review journals.
2019冠状病毒病（COVID-19）是一种由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的极具传染性和致病性的病毒感染，该病毒最初出现在中国武汉。目前，COVID-19尚无特效治疗方法。美国食品药品监督管理局（FDA）已批准瑞德西韦作为第一种治疗COVID-19的药物。然而，许多其他治疗方法也正在作为COVID-19的可能治疗手段进行研究。作为本综述的一部分，我们讨论了各种药物的研发、作用机制以及它们如何应用于不同病例的COVID-19患者。此外，本综述还重点介绍了针对COVID-19的新型预防性或治疗性疫苗的最新进展。除了FDA或世界卫生组织（WHO）批准的疫苗外，我们还纳入了来自不同COVID-19疫苗III期试验的最新发表数据，并提供在网络或同行评审期刊上发布的临床数据。
